Menu

How Did Johnson & Johnson Stock Prices React to Its Vaccine Suspension?

Plus500 | Wednesday 14 April 2021

On Tuesday, the U.S. federal government asked state health officials to suspend the use of the Johnson & Johnson COVID-19 vaccine after six recipients developed a rare blot clot disorder. The Biden administration insists that this will not delay the country’s vaccination plan, which aims to have 200 million Americans vaccinated by the end of April 2021. Johnson & Johnson shares were down 1.3% yesterday.

Vaccine

The J & J (JNJ) vaccine was the third to be approved for emergency use by the FDA and CDC, after ones produced by Moderna (MRNA) and Pfizer (PFE). As it requires only one injection and can be stored at higher temperatures than the other vaccines, it was primarily designated for hard-to-reach populations. Some of the reasons the suspension was put in place include allowing time for physicians to learn how to treat patients who develop symptoms consistent with blood clots, along with looking for additional cases other than the six which have already been publicized.

The Johnson & Johnson vaccine is based on an adenovirus, a harmless virus related to the common cold. This is similar to the AstraZeneca (AZN-L) vaccine which is used extensively in Europe, and which was also suspended temporarily for problems with blood clots last month. One difference is that the J & J vaccine is based on a human cold virus, while AstraZeneca relies upon a chimpanzee version of the virus. Yesterday, Canada reported their first case of blood clots possibly related to the AstraZeneca vaccine. AstraZeneca shares went up about 0.9% on Wednesday morning.

Moderna Stock Price Jumps as Vaccine Shows Effectiveness 

Moderna offered some positive news yesterday in the fight against COVID-19. The company announced that data from its phase three clinical trials showed that its vaccine was more than 90% effective at protecting against COVID-19 for up to six months after the second shot. Additionally, the vaccine was 95% effective at preventing serious disease during the same time period, based on 900 cases followed through April 9, 2021. Moderna share prices jumped by 7.4% yesterday.

Johnson was handed a setback yesterday in its vaccine delivery. It remains to be seen whether the suspension will continue to affect its stock prices going forward.


Get more from Plus500

Expand Your Knowledge

Videos & Articles help you expand your trading knowledge.

Prepare Your Trades

Our Economic calendar helps you explore global market events.

Trade Without Surprises

Understand the full costs of your trades now for better expense management later.


This information is written by Plus500 Ltd. The information is provided for general purposes only, and does not take into account any personal circumstances or objectives. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. No representation or warranty is given as to the accuracy or completeness of this information. It does not constitute financial, investment or other advice on which you can rely. Any references to past performance, historical returns, future projections, and statistical forecasts are no guarantee of future returns or future performance. Plus500 will not be held responsible for any use that may be made of this information and for any consequences that may result from such use. Hence, any person acting based on this information does so at their own discretion. The information has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

Need Help?
24/7 Support